Every material Form 8-K DiaMedica Therapeutics Inc. has filed with the SEC since March 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
DiaMedica reported a second-quarter 2026 net loss of $10.1 million, up from $7.7 million a year earlier, as R&D spending rose. The company had $43.5 million in cash and investments at June 30, 2026, down from $59.9 million at December 31, 2025, and said this should fund planned studies and operations through 2027. The filing also reports positive preeclampsia Phase 2 topline results, which shareholders will weigh against the higher losses and lower cash balance.
Q2 2026 net loss was $10.1 million, or $0.19 per share, versus a net loss of $7.7 million, or $0.18 per share, in Q2 2025.
Six-month net loss was $20.2 million, up from $15.4 million; R&D expenses for the six months were $16.1 million, up from $11.5 million.
Cash, cash equivalents and short-term investments were $43.5 million at June 30, 2026, versus $59.9 million at December 31, 2025; the company expects to fund operations through 2027.
Preeclampsia Phase 2 Part 1a reported a mean 29.1 mmHg reduction in systolic blood pressure in the combined final cohorts; the company will hold a key opinion leader call with FGR topline results in September.
DiaMedica reported a first-quarter 2026 net loss of $10.0 million, up from $7.7 million a year earlier, as research and development spending rose on its ReMEDy2 stroke trial and preeclampsia program. Cash and short-term investments fell to $51.3 million from $59.9 million at December 31, 2025, and the company says that balance will fund planned studies through 2027, which matters to shareholders because the company reports no revenue and depends on outside funding.
Net loss was $10.0 million for the quarter ended March 31, 2026, compared with $7.7 million a year earlier.
Research and development expenses rose to $8.0 million from $5.7 million, driven mainly by the ReMEDy2 trial and related expansion.
Cash and short-term investments were $51.3 million at March 31, 2026, versus $59.9 million at December 31, 2025, and are expected to last through 2027.
Net loss per share was $0.19, compared with $0.18 a year earlier, on 53,793,490 weighted average shares.
DiaMedica Therapeutics reported full-year 2025 results showing a wider net loss of $32.8 million, or $0.70 per share, compared with $24.4 million, or $0.60 per share, in 2024, as research and development and general and administrative costs rose. The company ended 2025 with $59.9 million in cash and short-term investments, which it says will fund operations through the second half of 2027, after share sales in July 2025 and under its at-the-market program.
Net loss for 2025 was $32.8 million, or $0.70 per share, versus $24.4 million, or $0.60 per share, in 2024.
Research and development expenses rose to $24.6 million from $19.1 million, driven mainly by the ReMEDy2 trial and its global expansion.
General and administrative expenses rose to $9.8 million from $7.6 million, including higher share-based compensation.
Cash and short-term investments were $59.9 million at December 31, 2025, up from $44.1 million a year earlier.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DiaMedica Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →